Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program
30 mars 2020 07h00 HE
|
Ergomed plc
PRESS RELEASE Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program Guildford, UK – 30 March 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the...
Audited Full Year Results for the year ended 31 December 2019
25 mars 2020 07h00 HE
|
Ergomed plc
PRESS RELEASE Audited Full Year Results for the year ended 31 December 2019 Revenue £68.3m (up 26.1%) Adjusted EBITDA £12.5m (up from £2.3m in 2018) Order book of future contracted revenue £124.1...
Ergomed Announces Provision of Clinical Research Services for COVID-19 Clinical Study
18 mars 2020 07h00 HE
|
Ergomed plc
RNS REACHPRESS RELEASE Ergomed Announces Provision of Clinical Research Services for COVID-19 Clinical Study Guildford, UK – 18 March 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a...
2019 Trading Update
29 janv. 2020 07h00 HE
|
Ergomed plc
PRESS RELEASE Ergomed 2019 Trading Update 2019 EBITDA ahead of market expectations Outlook underpinned by strong order book and Ashfield Pharmacovigilance acquisition Guildford, UK – 29 January...
Acquisition of Ashfield Pharmacovigilance Inc., a US pharmacovigilance services provider, from UDG Healthcare for $10 million
13 janv. 2020 09h00 HE
|
Ergomed plc
PRESS RELEASE Acquisition of Ashfield Pharmacovigilance Inc., a US pharmacovigilance services provider, from UDG Healthcare for $10 million Ashfield Pharmacovigilance Inc. becomes part of Ergomed’s...
Ergomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study
23 oct. 2017 02h11 HE
|
Ergomed plc
PRESS RELEASE Ergomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study Highly innovative blood free haemostat met the...